CONCENTRATIONS AND UNCERTAINTIES	3 Months Ended
Nov. 30, 2021
Risks and Uncertainties [Abstract]
CONCENTRATIONS AND UNCERTAINTIES	NOTE 9: CONCENTRATIONS AND UNCERTAINTIES Financial instruments that potentially subject us to concentration of credit risk consist principally of cash, cash equivalents, trade accounts receivable, and short-term investments. We hold cash and cash equivalents at banks located in California and with balances that often exceed FDIC-insured limits. In addition, we hold cash at a bank in France that is not FDIC-insured. Historically, we have not experienced any losses in such accounts. However, we are investigating alternative ways to minimize our exposure to such risks. While we may be exposed to credit losses due to the nonperformance of our counterparties, we do not expect the settlement of these transactions to have a material effect on our results of operations, cash flows, or financial condition. We maintain cash at financial institutions that may, at times, exceed federally insured limits. Revenue concentration shows that international sales accounted for 31% and 33% of net sales for the three months ended November 30, 2021 and 2020, respectively. Four customers accounted for 7%, 5%, 5%, and 5% of net sales during the three months ended November 30, 2021. Three customers accounted for 17%, 7%, and 5% of net sales during the three months ended November 30, 2020. Accounts receivable concentration shows that five customers each comprised between 5% and 21% of accounts receivable as of November 30, 2021 compared to five customers each comprising between 6% and 21% of accounts receivable as of November 30, 2020. We operate in the computer software industry, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products. The majority of our customers are in the pharmaceutical industry. During economic downturns, we have seen consolidations in the pharmaceutical industry. The extent to which the COVID-19 pandemic continues to impact our business going forward will depend on numerous factors we cannot reliably predict, including the duration and scope of the pandemic; businesses, and individuals' actions in response to the pandemic; and the impact on economic activity, including the possibility of recession or financial market instability. These factors may adversely impact consumer, business, and government spending as well as customers' ability to pay for our products and services on an ongoing basis. As a result, our growth rate could be affected by consolidation and downsizing in the pharmaceutical industry.

CONCENTRATIONS AND UNCERTAINTIES

3 Months Ended

Nov. 30, 2021

NOTE 9: CONCENTRATIONS AND UNCERTAINTIES

Financial instruments that potentially subject us to concentration of credit risk consist principally of cash, cash equivalents, trade accounts receivable, and short-term investments. We hold cash and cash equivalents at banks located in California and with balances that often exceed FDIC-insured limits. In addition, we hold cash at a bank in France that is not FDIC-insured. Historically, we have not experienced any losses in such accounts. However, we are investigating alternative ways to minimize our exposure to such risks. While we may be exposed to credit losses due to the nonperformance of our counterparties, we do not expect the settlement of these transactions to have a material effect on our results of operations, cash flows, or financial condition. We maintain cash at financial institutions that may, at times, exceed federally insured limits.

Revenue concentration shows that international sales accounted for 31% and 33% of net sales for the three months ended November 30, 2021 and 2020, respectively. Four customers accounted for 7%, 5%, 5%, and 5% of net sales during the three months ended November 30, 2021. Three customers accounted for 17%, 7%, and 5% of net sales during the three months ended November 30, 2020.

Accounts receivable concentration shows that five customers each comprised between 5% and 21% of accounts receivable as of November 30, 2021 compared to five customers each comprising between 6% and 21% of accounts receivable as of November 30, 2020.

We operate in the computer software industry, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products.

The majority of our customers are in the pharmaceutical industry. During economic downturns, we have seen consolidations in the pharmaceutical industry. The extent to which the COVID-19 pandemic continues to impact our business going forward will depend on numerous factors we cannot reliably predict, including the duration and scope of the pandemic; businesses, and individuals' actions in response to the pandemic; and the impact on economic activity, including the possibility of recession or financial market instability. These factors may adversely impact consumer, business, and government spending as well as customers' ability to pay for our products and services on an ongoing basis. As a result, our growth rate could be affected by consolidation and downsizing in the pharmaceutical industry.